The tariff classification of Gemfibrozil (CAS-25812-30-0) imported in dosage/tablet form, from India
Issued February 26, 2008 by U.S. Customs and Border Protection.
Tariff classification
HTS codes: 3004.90.9120
Headings: 3004
Product description
Gemfibrozil in dosage form is a medicinal preparation containing Gemfibrozil, an antihyperlipidemic drug used in the treatment of elevated cholesterol, as the active ingredient.
CBP rationale
The applicable subheading for Gemfibrozil, imported in dosage form, will be 3004.90.9120, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Medicaments … consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses … or in forms or packings for retail sale: Other: Other: Other: Cardiovascular medicaments.
Full text
N023638 February 26, 2008 CLA-2-30:OT:RR:E:NC:2:238 CATEGORY: Classification TARIFF NO.: 3004.90.9120 Mr. Colm F. Moynihan NorthStar Healthcare Limited 3300 Cork Airport Business Park Kinsale Road Cork, Ireland RE: The tariff classification of Gemfibrozil (CAS-25812-30-0) imported in dosage/tablet form, from India Dear Mr. Moynihan: In your letter dated February 22, 2008 you requested a tariff classification ruling. Gemfibrozil in dosage form is a medicinal preparation containing Gemfibrozil, an antihyperlipidemic drug used in the treatment of elevated cholesterol, as the active ingredient. The applicable subheading for Gemfibrozil, imported in dosage form, will be 3004.90.9120, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Medicaments … consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses … or in forms or packings for retail sale: Other: Other: Other: Cardiovascular medicaments.” The rate of duty will be free. Duty rates are provided for your convenience and are subject to change. The text of the most recent HTSUS and the accompanying duty rates are provided on World Wide Web at http://www.usitc.gov/tata/hts/. This merchandise may be subject to the Federal Food, Drug, and Cosmetic Act and/or The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (The Bioterrorism Act), which are administered by the U.S. Food and Drug Administration (FDA). Information on the Federal Food, Drug, and Cosmetic Act, as well as The Bioterrorism Act, can be obtained by calling the FDA at 1-888-463-6332, or by visiting their website at www.fda.gov. This ruling is being issued under the provisions of Part 177 of the Customs Regulations (19 C.F.R. 177). A copy of the ruling or the control number indicated above should be provided with the entry documents filed at the time this merchandise is imported. If you have any questions regarding the ruling, contact National Import Specialist Harvey Kuperstein at 646-733-3033. Sincerely, Robert B. Swierupski Director, National Commodity Specialist Division
More rulings on the same tariff codes
The tariff classification of Olmesartan Medoxomil Tablets and Spironolactone Tablets in dosage form, from India and China, respectively
The tariff classification of Bosentan Tablets in dosage form, from India
The tariff classification of Lisinopril Tablets, in dosage form, from India
The tariff classification of Enalapril Maleate Tablets, imported in dosage form, from Slovenia
The tariff classification of Xarelto® tablets in dosage form from Germany
The tariff classification of Adempas tablets in dosage form from Germany
The tariff classification of Metoprolol Succinate Extended Release Tablets and Candesartan Cilexetil Tablets, imported in dosage form, from India
The tariff classification of Ramipril Tablets, imported in dosage form, from India
The tariff classification of Sildenafil Tablets, imported in dosage form, from India
The tariff classification of Amlodipine Besylate (CAS-111470-99-6) and Benazepril Hydrochloride (CAS-86541-74-4), imported in dosage form, from India
Searching CBP rulings the smart way
TariffLens semantically searches all 200,000+ CBP rulings, surfaces the ones that actually match your product, and builds defensible classifications backed by ruling citations.
Book a demo →